BioCanada

Found 33,921 articles

• Greenbrook TMS Announces US$8.25 Million Equity and Debt Financings

  3/24/2023

  Greenbrook TMS Inc. today announced that it has (i) completed a non-brokered private placement of common shares of the Company for aggregate gross proceeds of approximately US$6.25 million.

• Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

  3/24/2023

  Spectral Medical Inc. today announced its financial results for the fourth quarter and for the year ended December 31, 2022 and provided a corporate update.

• SQI DIAGNOSTICS ANNOUNCES PROPOSED INSIDER SALES AND WARRANT EXERCISES TO FUND COMPANY

  3/24/2023

  SQI Diagnostics Inc. announces that certain insiders of the Company, who are also control persons of the Company and collectively own, or exercise control or direction over, an aggregate of 75% of the issued and outstanding common shares.

• Savaria Declares Monthly Dividend - March 24, 2023

  3/24/2023

  Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, declared today a dividend of 4.33 cents ($0.0433) per common share, in accordance with its monthly dividend policy, payable on April 10, 2023, to shareholders of record of the Corporation at the close of business on March 31, 2023.

• Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

  3/24/2023

  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis.

• IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023

  3/24/2023

  IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 29, 2023.

• Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

  3/23/2023

  Aeterna Zentaris Inc. today reported its financial and operating results for the year ended December 31, 2022.

• Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

  3/23/2023

  Ceapro Inc. announced that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.

• Sirona Biochem Announces Debenture Financing

  3/23/2023

  Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.

• Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

  3/23/2023

  Today, Arch Biopartners Inc. announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program.

• Aptose Reports Results for the Fourth Quarter and Full Year 2022

  3/23/2023

  Aptose Biosciences Inc. announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

• IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow

  3/23/2023

  IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023.

• Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

  3/23/2023

  Health Canada has granted marketing authorization for SPEVIGO® (spesolimab for injection) for the treatment of flares in adult patients with generalized pustular psoriasis (GPP), Boehringer Ingelheim (Canada) Ltd. has announced today.

• Predictmedix Expands on Non-Invasive AI-powered Impairment Detection Technology for Vertical-Specific Applications

  3/23/2023

  Predictmedix Inc. is excited to announce an update on the functionality and application of their technology across specific verticals.

• Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million

  3/23/2023

  Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023

• Therma Bright Prepares Launch of Digital Cough Screening and Data Collection Smartphone Application

  3/23/2023

  Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company and AI4LYF are preparing to launch DCT, its digital cough data collection and screening smartphone application.

• Sona Nanotech Closes Acquisition of Siva Therapeutics, Plans For First Therapy Application for Colorectal Cancer

  3/23/2023

  Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has closed its previously announced acquisition of Siva Therapeutics, Inc. ("Siva"). Pursuant to the share exchange agreement announced on January 26, 2023,

• ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

  3/23/2023

  Immunoprecise Antibodies Ltd. will present a scientific poster with their latest data on the development of bispecific T-cell engagers targeting TrkB at the annual AACR meeting in Orlando, Florida, which is held from April 14 to 19, 2023.

• Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

  3/23/2023

  Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023.

• FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder

  3/22/2023

  FSD Pharma Inc. today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics Committee in Australia to proceed with a Phase 1 study.